zurück

Capmatinib (non-small cell lung cancer (NSCLC), pretreated patients with mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping)

 

Subject:

  • Active Sustance: Capmatinib
  • Name: Tabrecta®
  • Therapeutic area: Non-small cell lung cancer (NSCLC)
  • Pharmaceutical company: Novartis Pharma GmbH

 

Time table:

  • Start: 15.08.2022
  • Final decision by G-BA: 02.02.2023

 

Final decision:

  1. Patients after first-line therapy with a PD-1/PD-L1 antibody as monotherapy: No additional benefit proven
  2. Patients after first-line therapy with platinum-containing therapy: No additional benefit proven
  3. Patients after first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing therapy: No additional benefit proven